Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care.
BACKGROUND
Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies.


OBJECTIVE
To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp).


METHODS
Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 +/- 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses.


RESULTS
Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy.


CONCLUSIONS
A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.
Germaná
B
B
Gastroenterology Unit, S. Martino Hospital, Belluno, Italy.
Di Mario
F
F
Cavallaro
L G
LG
Moussa
A M
AM
Lecis
P
P
Liatoupolou
S
S
Comparato
G
G
Carloni
C
C
Bertiato
G
G
Battiestel
M
M
Papa
N
N
Aragona
G
G
Cavestro
G M
GM
Iori
V
V
Merli
R
R
Bertolini
S
S
Caruana
P
P
Franzé
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000032:analysis*; D002908:Chronic Disease; D004415:Dyspepsia / Q000097:blood* / Q000209:etiology; D005260:Female; D005755:Gastrins / Q000097:blood*; D005756:Gastritis / Q000150:complications / Q000175:diagnosis* / Q000382:microbiology; D005773:Gastroscopy; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D020116:Pepsinogen A / Q000097:blood*; D020115:Pepsinogen C / Q000097:blood*; D011320:Primary Health Care
D000907:Antibodies, Bacterial; D005755:Gastrins; D007074:Immunoglobulin G; C013550:gastrin 17; D020115:Pepsinogen C; D020116:Pepsinogen A